This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP using a rapid, scalable, and high-fidelity process free from animal-derived components, dbDNA eliminates the need for bacterial fermentation and master cell banks, significantly reducing the risk of bacterial impurities.

Expression Manufacturing evaluated dbDNA against pDNA in both 3rd-generation and LentET 2.5 LVV systems using ET3 and GFP transgenes. Results demonstrated higher infectious titres and an improved safety profile with dbDNA, underscoring its potential to enhance LVV yields and reduce cost of goods through optimised transfection efficiency.

Download the application note to learn:

• How dbDNA supports both 2.5th and 3rd generation LVV systems, demonstrating flexibility across vector design platforms
•  The potential for reduced cost of goods in LVV manufacturing due to dbDNA’s lower DNA input requirements and streamlined production
• Experimental results showing up to 40% higher infectious titres with dbDNA packaging constructs compared to pDNA when using a clinical-stage transgene